Tukysa (tucatinib) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

Instructions: Please fill out all applicable sections completely and legibly. Attach any additional documentation that is important for the review (e.g., chart notes or lab data, to support the authorization request). Information contained in this form is Protected Health Information under HIPAA.

			URGENI		
MEMBER INFORMATION					
LAST NAME:		FIRST NAME:			
PHONE NUMBER:		DATE OF BIRTH:			
STREET ADDRESS:	STREET ADDRESS:				
CITY:		STATE: ZIP CODE:			
PATIENT INSURANCE ID NUMBER:					
MALE FEMALE HEIGHT (IN/CM): WEIGHT (LB/KG): ALLERGIES:					
IF YOU ARE NOT THE PATIENT OR THE PRESCRIBER, YOU WILL NEED TO SUBMIT A PHI DISCLOSURE AUTHORIZATION FORM WITH THIS REQUEST WHICH CAN BE FOUND AT THE FOLLOWING LINK: PRIMETHERAPEUTICS.COM/NOPP					
PATIENT'S AUTHORIZED REPRESENTATIVE (IF APPLICABLE):					
PRESCRIBER INFORMATION					
LAST NAME:		FIRST NAME:			
PRESCRIBER SPECIALTY:		EMAIL ADDRESS:			
NPI NUMBER:		DEA NUMBER:			
PHONE NUMBER:		FAX NUMBER:			
STREET ADDRESS:					
CITY:		STATE: ZIP CODE:			
REQUESTOR (if different than prescriber):		OFFICE CONTACT PERSON:			
MEDICATION OR MEDICAL DISPENSING INFORMATION					
MEDICATION NAME:					
DOSE/STRENGTH:	FREQUENCY:	LENGTH OF THERAPY/REFILLS:	QUANTITY:		
☐ NEW THERAPY	RENEWAL	IF RENEWAL: DATE THERAPY	INITIATED:		
DURATION OF THERAPY (SPECIFIC DATES):					

Continued on next page.



Tukysa (tucatinib) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:	MEMBER'S FIRST NAME:			
1. HAS THE PATIENT TRIED ANY OTHE	R MEDICATIONS FOR THIS CONDITION?	YES (if yes, complete below) NO		
MEDICATION/THERAPY (SPECIFY DRUG NAME AND DOSAGE):	DURATION OF THERAPY (SPECIFY DATES):	RESPONSE/REASON FOR FAILURE/ALLERGY:		
2. LIST DIAGNOSES:		ICD-10:		
☐ Advanced, unresectable HER2-positive b	reast cancer			
☐ Metastatic HER2-positive breast cancer☐ Other diagnosis:	ICD-10			
	: PLEASE PROVIDE ALL RELEVANT CLINIC	AL INFORMATION TO SUPPORT A		
Clinical Information:				
Is this drug being prescribed to this patrial? Yes No	atient as part of a treatment regimen sp	ecified within a sponsored clinical		
	with one or more antiHER2-based regiments ${\sf deg}(x)$ in the metastatic setting? ${\sf deg}(x)$	•		
 Will patient use Tukysa(tucatinib) in combination with trastuzumab AND capecitabine? □ Yes □ No				
Has patient had prior use of Lenvima(lapatinib) in the past 12 months? \Box Yes	□ No		
If patient had prior use of Lenvima(laptherapy? Yes No	patinib) in the past 12 months, did the p	atient receive less than 22 days of		
Did the patient discontinue the Lenvir ☐ Yes ☐ No	ma(lapatinib) for reasons other than dis	ease progression or toxicity?		
Has patient had prior use of neratinib inhibitors? ☐ Yes ☐ No	(Nerlynx), afatinib(Gilotrif) or other HEF	R2 EGFR or HER2 tyrosine kinase		
Has patient had prior use of capecitab	oine or other fluoropyrimidines for meta	astatic disease? □ Yes □ No		
If Yes, Was capecitabine or other fluorago? ☐ Yes ☐ No	ropyrimidines used in adjuvant/neoadju	evant treatment less than 12months		
If patient has had prior use of capecita receive less than 22 days of therapy?	abine or other fluoropyrimidines for me	tastatic disease, did the patient		
Did the patient discontinue prior use other than disease progression or tox	of capecitabine or other fluoropyrimidiricity? Yes No	nes for metastatic disease for reasons		
Does the patient have leptomeningea	l disease? □ Yes □ No			



Tukysa (tucatinib) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

IVIEIVIDER 3 LAST INAIVIE:	IVICIVIDER 3 FIRS	I NAIVIE.
Are there any other comments, diagnoses, physician feels is important to this review?		failed, and/or any other information the
Please note: Not all drugs/diagnosis are covinformation is received.	rered on all plans. This request ma	y be denied unless all required
ATTESTATION: I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan, insurer, Medical Group or its designees may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.		
Prescriber Signature or Electronic I.D. Verif	ication:	Date:
confidentiality notice: The documents accompany you are not the intended recipient, you are hereby no of these documents is strictly prohibited. If you have not arrange for the return or destruction of these documents.	tified that any disclosure, copying, distrik received this information in error, please	oution, or action taken in reliance on the contents

FAX THIS FORM TO: 800-424-7640

MAIL REQUESTS TO: Prime Therapeutics Management Prior Authorization Program

Attn: CP – 4201 P.O. Box 64811 St. Paul, MN 55164-0811

